Profile: GenVec Inc (GNVC.OQ)

GNVC.OQ on NASDAQ Stock Exchange Capital Market

3.43USD
28 Jan 2015
Change (% chg)

$-0.01 (-0.29%)
Prev Close
$3.44
Open
$3.49
Day's High
$3.60
Day's Low
$3.42
Volume
3,892
Avg. Vol
17,265
52-wk High
$4.11
52-wk Low
$1.61

Search Stocks

GenVec, Inc. (GenVec), incorporated in 1992, is a biopharmaceutical company, engaged in the creation of therapeutics and vaccines. The Company works with companies and organizations, such as Novartis, Merial and the United States Government to support a range of product programs that address the prevention and treatment of a number of human and animal health concerns. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company’s products are developed with its adenovector technology, which uses modified adenoviruses to deliver genes to target cells.

The Company, in partnership with its collaborators has started working on multiple vaccines, which are in development stage. These programs utilize its core adenovector technology. It started preclinical programs to develop vaccine candidates for the prevention of RSV and HSV. The Company works with Novartis Institutes for BioMedical Research, Inc. (together with Novartis AG and its subsidiary corporations, including Novartis Pharma AG, Novartis), on the discovery and development of treatments for hearing loss and balance disorders. In the field of animal health, the Company is working with Merial Limited to commercialize vaccines for the prevention of an animal health problem, FMD.

Hearing and Balance Program

In collaboration with Novartis, the Company’s hearing and balance disorders program is involved in the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. Hearing and balance require specialized cells of the inner ear called sensory hair cells. Embryonic development is an atonal gene (Atoh1) induces the generation of these cells. In multiple animal models, the Company has demonstrated formation of new inner ear sensory hair cells and the restoration of hearing and balance function using its technology to deliver the Atoh1 gene to the inner ear.

Vaccine Development Programs

In addition to the Company’s therapeutic product development programs, it is working with collaborators to develop vaccines using its adenovector technology. It is developing preventative vaccines, including RSV, HSV, dengue fever, and malaria.

The Company competes with Sanofi S.A., Novartis, GlaxoSmithKline plc, MedImmune, Inc., (a wholly owned subsidiary of AstraZeneca), Merck & Co., Inc., Pfizer Inc., Crucell N.V., Bavarian Nordic A/S, Okairos S.r.l. (acquired by GlaxoSmithKline in 2013), Intercell A.G., Genocea BioSciences Inc., Vical Incorporated, Emergent Biosolutions Inc. and Novavax Inc., among others.

Company Address

GenVec Inc

910 Clopper Rd Ste 220n
GAITHERSBURG   MD   20878-1353
P: +1240.6320740
F: +1240.6320735

Company Web Links

Search Stocks